Remove 2017 Remove Insurance Remove Labelling
article thumbnail

Wegovy facts and statistics 2025

The Checkup by Singlecare

A monthly supply of Wegovy can cost more than $1,800 without insurance. However, growing insurance coverage and savings programs are helping to make it more accessible. According to 2017–2018 data, about 31% of Americans were classified as overweight. How many Americans use insurance for Wegovy? About 1 in 6 (16%) of U.S.

article thumbnail

Fentanyl facts and statistics

The Checkup by Singlecare

It can be prescribed off-label for certain types of pain, especially severe acute pain or pain caused by cancer. Fentanyl may also be prescribed off-label, meaning for a purpose other than what the Food and Drug Administration (FDA) approved it for. was over $1 trillion in 2017. As of Sept. For example: A 2021 study of U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Obesity Medication Use Remains Low Among Children | ADA 2025

Drug Topics

from 2017 to 2020. of YA with obesity were prescribed OMs—predominantly GLP-1s approved for adults but used off label for younger people. Children today are less active than they used to be—and they’re also facing an increased amount of stress.” 3 Researchers believe more needs to be done to treat obesity among the younger population.

article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

J&J bids to extend prostate cancer uses for Akeega

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in Milan, Italy, preliminary dose-escalation and optimisation results from the global, multicentre, open-label, single-arm Phase I/II SYRUS clinical trial (NCT06137118) were presented on the second day.

article thumbnail

Can I take Ozempic if I’m not diabetic?

The Checkup by Singlecare

Although GLP-1 drugs have been around since 2005, Ozempic was only made available in 2017. Taking medication for a reason that isn’t FDA approved is considered an “ off-label ” use. First, using a drug off-label—especially one that’s fairly new, like Ozempic—can be unsafe.